Legend Biotech Shares Fall After CEO Ying Huang Steps Down
Shares of the cell therapy company declined after it announced the immediate departure of its chief executive. Alan Bash, head of the CARVYKTI business unit, has been named interim CEO.
Latest by Marcus Chen
Entera Bio Secures $275 Million in Private Placement to Fund Osteoporosis Drug Trial
The biopharmaceutical company announced an oversubscribed private placement led by BVF Partners L.P., with proceeds intended to fund a Phase 3 trial for its oral osteoporosis treatment and extend its cash runway into 2030.
Elme Communities Shares Rise on New $250 Million Asset Sale Amid Liquidation
The real estate investment trust's stock gained after it announced a new sale agreement for its Riverside Apartments and updated its estimated liquidating distribution for shareholders.
Legend Biotech Stock Slides on CEO Departure, Compounding Analyst Concerns
Shares of Legend Biotech dropped after the company announced the departure of its long-serving CEO, adding to pressure from a recent analyst downgrade that cited rising competition for its key cancer therapy, Carvykti.
U.S. Stocks Open Higher as Easing U.S.-Iran Tensions Boost Sentiment
U.S. stock indexes climbed at Monday's open, with the Nasdaq leading gains, as a pause in hostilities between the United States and Iran improved risk appetite ahead of a key week for earnings and economic data.
Replimune Stock Slides Over 12% Ahead of Key FDA Panel for Melanoma Drug
Shares of the biotech company fell sharply as investors braced for a U.S. Food and Drug Administration advisory committee meeting for its lead cancer drug, RP1, which has faced two previous rejections.
Venture Global Stock Declines as Investors Take Profits After 23% Rally
Shares of the LNG developer are falling despite a broader market rally, as investors lock in recent gains amid a lack of new catalysts and ahead of its upcoming Q2 earnings report.
D-Wave Quantum Stock Jumps on Expanded AT&T Partnership, Nasdaq Debut
Shares of D-Wave Quantum (QBTS) surged after the company announced an expanded technology partnership with AT&T and completed its first day of trading on the Nasdaq exchange.
Cerebras Systems Stock Declines as Margin Concerns, Legal Overhang Weigh
Shares of the AI chipmaker extended a recent pullback on Monday, pressured by profit-taking, a previously disclosed hit to gross margins, and an ongoing securities investigation.